Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 7c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Join SI Premium – FREE
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.07), $0.07 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $47.07 million.
GUIDANCE:
Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of $223.2 million.
For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
